Abstract
A novel class of ruthenium (III) complexes of formulas K [ Ru ( sar ) 2 Cl 2 ] · 1 2 H 2 O and K 2[Ru(dmgly)Cl 4] · 2H 2O, containing bidentate chelates N-methylglycine (sarcosine, sar) or N, N-dimethylglycine (dmgly) and additional chloro ligands were synthesized. The complexes have been obtained by direct reaction of ruthenium(III) chloride with corresponding bidentate ligand followed by addition of base (KOH). These new complexes were characterized by elemental analysis, IR and electronic absorption spectroscopy. As astrocytomas, the most common of all brain tumors, are still very difficult to treat, we examined the influence of newly synthesized ruthenium-based complexes, as well as the earlier synthesized analogue platinum(IV) complexes [Pt(dmgly) 2Cl 2], [Pt(sar) 2Br 2] and [Pt(dmgly) 2Br 2], on rat astrocytoma C6 cells in vitro. Among these complexes only K 2[Ru(dmgly)Cl 4] · 2H 2O and [Pt(dmgly) 2Br 2] markedly inhibited the viability of non-confluent C6 cells. Furthermore, only complex K 2[Ru(dmgly)Cl 4] · 2H 2O was able to reduce viability in confluent C6 cultures. Importantly, this complex was not toxic to primary rat astrocytes or macrophages. Having in mind that appropriate chemotherapy should be effective against tumor cells without harming normal tissues, complex K 2[Ru(dmgly)Cl 4] · 2H 2O could be a promising agent for developing therapeutics against astrocytomas.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
